U.S. Pharmacist Weekly News Update
September 19, 2018

Diclofenac Linked to Higher Major Heart Risks Than Similar Drugs

Pharmacists might want to steer patients requiring NSAIDs away from diclofenac, new research suggests. The large Danish observational study found much higher risk of major cardiovascular events with that specific drug than acetaminophen and other anti-inflammatories. Here are the details.


Banned Stimulant Found Mislabeled in Weight-Loss, Sports/Energy Products
Products sitting on drugstore shelves might contain the stimulant higenamine, according to a new study. The potentially harmful substance has been banned by the World Anti-Doping Agency, and none of the supplements analyzed in the United States included accurate information on the quantity of higenamine. Here is more information, including where to get a list of the products.

Extending Propranolol Treatment Improves Success With Infantile Hemangioma

The success rate of oral propranolol treatment of high-risk infantile hemangioma may be significantly increased by extending treatment from 6 months to as long as a year, a new study determined. Find out how the longer duration of treatment affected safety issues in the infants.

Pharmacist/Telemonitoring Intervention Sustained BP-Lowering for 2 Years
A yearlong intervention involving pharmacists and telemonitoring equipment helped keep patients’ hypertension better controlled for at least 2 years, but a review raises questions on how that could be extended. What was the program, and how well did it work overall?

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App